Arcutis Biotherapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ARQT research report →
Range $38 – $48
Price Chart
About the company
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis.
- CEO
- Todd Franklin Watanabe
- IPO
- 2020
- Employees
- 354
- HQ
- Westlake Village, CA, US
Get TickerSpark's AI analysis on ARQT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.33B
- P/E
- 113.28
- Fwd P/E
- 95.61
- PEG
- 0.03
- P/S
- 6.55
- P/B
- 14.16
- EV/EBITDA
- 76.18
- Div Yield
- 0.00%
- Gross Margin
- 91.18%
- Op Margin
- 6.91%
- Net Margin
- 5.88%
- ROE
- 14.18%
- ROIC
- 9.51%
Latest fiscal year · YoY change
- Revenue
- $376.07M+91.3%
- Gross Profit
- $339.38M+91.3%
- Op Income
- $-12,227,000
- Net Income
- $-16,140,999+88.5%
- EPS
- $-0.13+88.8%
- OCF Growth
- +95.0%
- FCF Growth
- +94.4%
- 52W High
- $34.80
- 52W Low
- $19.30
- 50D MA
- $27.81
- 200D MA
- $25.41
- Beta
- 1.63
- RSI (14)
- 42
- Avg Volume
- 2.59M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Arcutis posted 45% year-over-year third-quarter revenue growth, raised full-year net revenue guidance, and laid out a broader 2027 growth plan built around ZORYVE expansion, new launches, and additional clinical readouts.· November 4, 2026
- Q3 net product revenue was $143.9 million, up 45% year over year and up 11% sequentially.
- Management raised 2026 net revenue guidance to $535 million-$545 million from $525 million-$540 million.
- Demand exceeded 300,000 prescriptions in the quarter, with growth across all indications and formulations.
- The company expects Q4 to be its strongest quarter seasonally and sees 2027 as an inflection year.
- Pipeline updates included a new moderate-to-severe atopic dermatitis trial, a February 23, 2027 PDUFA for infant AD, and upcoming vitiligo and HS readouts.
Third-quarter 2026 net product revenues were $143.9 million, up 45% from Q3 2025 and up 11% from Q2 2026. Gross-to-net remained in the low 50s / 50s and was stable sequentially, with only modest improvement driven mainly by lower co-pay expense. Cost of sales were $12.5 million versus $8.7 million a year ago; R&D was $22.4 million versus $19.6 million; SG&A was $99.6 million versus $62.4 million; and net income was $8.8 million versus $7.4 million. The company ended the quarter with $259.8 million of cash and marketable securities, generated $18.9 million of positive operating cash flow, and had $109.4 million of total debt. Full-year 2026 net revenue guidance was increased to $535 million-$545 million from $525 million-$540 million.
Frank Watanabe framed the quarter as continued execution across the company’s “grow, expand and build” strategy, saying Arcutis is reinvesting ZORYVE cash flow into commercial and clinical initiatives to drive sustained growth and sales inflection in 2027. He emphasized broadening ZORYVE’s reach through the Simone Biles campaign, virtual health, primary care/pediatrics, and multiple new clinical programs, while also highlighting a measured approach to AI with more than 30 identified use cases. His tone was confident and expansive, with repeated comments that the company is in the “right time” and “right place” with the “right drug.”
Latha Vairavan said Q3 revenue strength came primarily from increased patient demand, with gross-to-net still stable in the 50s and only very modest improvement. She pointed to higher spending in R&D and SG&A—especially media spend for the Skin to Believe In campaign and sales-force expansion—and said expenses should stay at this level in Q4 as Arcutis continues to invest for 2027 growth. She also said the company produced positive operating cash flow of $18.9 million, ended with $259.8 million in cash and marketable securities, carries $109.4 million of debt, and expects to remain positive cash flow through year-end while continuing to reinvest capital back into the business.
Analysts focused on the implied acceleration into 2027, the potential commercial opportunity from vitiligo and other new indications, and whether business development will be needed given the company’s cash generation. Management said 2027 growth should inflect as current investments mature, but declined to give a softer near-term sales guide. On new indications, Patrick Burnett said vitiligo and HS could involve longer-duration treatment than current approved uses, which could matter for utilization, but the company has not yet quantified tube usage; he also said a Phase III sketch would be shared with enough detail to explain the advancement decision, though final design will depend on FDA discussions. On BD, Frank Watanabe said external assets are a “nice to have, not a must-have,” and that Arcutis is being very disciplined, focusing mainly on late Phase II to early Phase III opportunities.
The call showed strong underlying commercial momentum, with demand and prescriptions still rising despite seasonal headwinds and management expecting Q4 strength plus further acceleration in 2027. ZORYVE now has multiple growth levers: broader awareness, better access, a larger field force, a new moderate-to-severe AD study, and potential label expansion into infants, vitiligo, HS, and checkpoint-inhibitor rash. Management was openly upbeat about the size of the opportunity and the company’s ability to self-fund growth from operating cash flow.
Management acknowledged that some of the commercial initiatives, including the Simone Biles campaign and new sales-force investments, will take time to show up in prescription growth, with more visible impact expected in early 2027. The company is also taking on meaningful SG&A and R&D spending, and several of the most interesting upside drivers are still early-stage or unproven, including the vitiligo and HS readouts and the new moderate-to-severe AD program. The call also made clear that 2027 visibility is not yet fully detailed, and any longer-term pipeline expansion will depend on clinical data and FDA alignment.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 87.1%
- Shares Outstanding
- 126.45M
- Float Shares
- 110.17M
of shares held by institutions
283 13F filers
Buy/sell ratio 0.71. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for ARQT, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Gilbert CisnerosHouse · CA31 | Buy | May 29, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Mar 3, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Sell | Dec 11, 25 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Sep 15, 23 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | Apr 17, 23 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | Jun 15, 22 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 19.17M | ▲ 8.63M |
| Montanova Capital, LLC | 12.27M | ▼ 168.00K |
| Frazier Life Sciences Management, L.P. | 9.87M | 0 |
| Rubric Capital Management LP | 8.42M | ▲ 150.00K |
| State Street Corp | 7.72M | ▲ 1.90M |
| Vanguard Group Inc | 7.25M | ▲ 107.85K |
| Polar Capital Holdings PLC | 6.59M | ▼ 14.83K |
| Ubs Group AG | 5.53M | ▲ 2.20M |
| Morgan Stanley | 5.30M | ▲ 845.52K |
| Vanguard Capital Management LLC | 4.99M | ▲ 5.29K |
| Vanguard Portfolio Management LLC | 3.82M | ▲ 1.39M |
| Bank Of America Corp | 3.49M | ▲ 506.46K |
Held by 320 ETFs
Biggest fund positions in ARQT by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 16, 26 | Welgus Howard G. | other | 2,254 |
| Nov 16, 26 | Welgus Howard G. | other | 1,018 |
| Nov 16, 26 | Welgus Howard G. | other | 822 |
| Nov 16, 26 | Welgus Howard G. | sell | 4,728 |
| Nov 16, 26 | Welgus Howard G. | other | 2,254 |
| Nov 16, 26 | Welgus Howard G. | other | 1,018 |
| Nov 16, 26 | Welgus Howard G. | other | 822 |
| Nov 13, 26 | Watanabe Todd | other | 144,232 |
| Nov 4, 26 | Matsuda Masaru | other | 40,000 |
| Nov 4, 26 | Matsuda Masaru | other | 40,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ARQT coverage
Recent articles, reports, and earnings notes.

Rezera Inc. IPO: What Investors Need to Know
Rezera Inc. is expected to list on NASDAQ on 2026-11-12 under the symbol RZRA, with shares priced in a $11.00 to $13.00 range. The company is offering 16,666,667 shares in a clinical-stage biotech IPO built around oral NLRP3 inhibitors. The bull case is a large unmet need in PAD and a pipeline with strategic backers; the bear case is that Rezera has no revenue, no approved product, and a long clinical path ahead.

What to Watch as Bambusa Therapeutics Prices Its Nasdaq IPO
Bambusa Therapeutics Inc. (Nasdaq: BBTX) is expected to list on 2026-10-30, with pricing already set for the NASDAQ. The company has not disclosed a price range, but it sold 10,555,555 shares at $16.00 each for $168.9 million in gross proceeds. Bulls will focus on its long-acting bispecific pipeline in immunology and inflammation; bears will focus on clinical risk and a cash runway that the company says is not enough to fund 12 months of operations.

Devonian Health Group IPO: The Bull and Bear Case
Devonian Health Group Inc. (NYSE: DHGR) is expected to list on 2026-08-21, but the company has not disclosed a price range yet. The setup is a clinical-stage biotech story with a commercial distribution business behind it, which gives it a real revenue base but also a financing-heavy path ahead.
Want a deeper read on ARQT?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Arcutis Biotherapeutics, Inc. $ARQT Stock Bought by Aberdeen Group plc
defenseworld.net · Nov 17
Arcutis Presents New Caregiver-Reported Outcomes Data Supporting ZORYVE® (roflumilast) Cream 0.05% for Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months at the ACAAI Annual Scientific Meeting
globenewswire.com · Nov 13
Arcutis Biotherapeutics (NASDAQ:ARQT) EVP Sells $1,372,800.00 in Stock
defenseworld.net · Nov 7
Arcutis Biotherapeutics (NASDAQ:ARQT) EVP Sells $1,372,800.00 in Stock
defenseworld.net · Nov 7
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Nov 6
Arcutis Begins Enrolling Phase 3 Study Evaluating ZORYVE® (roflumilast) Cream 0.3% in Moderate to Severe Atopic Dermatitis
globenewswire.com · Nov 5
Arcutis Biotherapeutics, Inc. (ARQT) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 4
Arcutis Biotherapeutics Q3 Earnings Call Highlights
marketbeat.com · Nov 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.